Patent ID: 11866446
Assignee: VERTEX PHARMACEUTICALS INCORPORATED
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC C

Claim 26:
27. The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1, wherein Ra, for each occurrence, is independently selected from halogen, cyano, C1-C6 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, —C(═O)NRhRi, —NRhRi, —NRhC(═O)Rk, —ORk, —[O(CH2)q]rO(C1-C4 alkyl), —S(═O)2Rk, —S(═O)2NRhRi, cyclopropyl, cyclobutyl, 5 to 6-membered heterocyclyl, phenyl, and 5 to 6-membered heteroaryl; wherein:
the C1-C6 alkyl of Ra is optionally substituted with 1 to 3 groups independently selected from cyano, —C(═O)NRhRi, —NRhRi, —ORk, cyclopropyl, and cyclobutyl;
the cyclopropyl, the cyclobutyl, the 5 to 6-membered heterocyclyl, the phenyl, and the 5 to 6-membered heteroaryl of Ra are each optionally substituted with 1 to 3 groups independently selected from halogen, —CH3, —OH, and —OCH3; wherein:
Rh and Ri, for each occurrence, are each independently selected from hydrogen, —CH3, cyclopropyl, and cyclobutyl; wherein:
the —CH3 of any one of Rh and Ri is optionally substituted with 1 to 3 groups independently selected from F, Cl, and —OH;

Rk, for each occurrence, is each independently selected from hydrogen and

CH3; wherein:
the —CH3 of Rk is optionally substituted with 1 to 3 groups independently selected from halogen and —OH.